127 related articles for article (PubMed ID: 22760702)
1. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).
Williams EL; Tutt AL; French RR; Chan HT; Lau B; Penfold CA; Mockridge CI; Roghanian A; Cox KL; Verbeek JS; Glennie MJ; Cragg MS
Eur J Immunol; 2012 Aug; 42(8):2109-20. PubMed ID: 22760702
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
Williams EL; Tutt AL; Beers SA; French RR; Chan CH; Cox KL; Roghanian A; Penfold CA; Butts CL; Boross P; Verbeek JS; Cragg MS; Glennie MJ
J Immunol; 2013 Oct; 191(8):4130-40. PubMed ID: 24026082
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Veri MC; Gorlatov S; Li H; Burke S; Johnson S; Stavenhagen J; Stein KE; Bonvini E; Koenig S
Immunology; 2007 Jul; 121(3):392-404. PubMed ID: 17386079
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Clynes RA; Towers TL; Presta LG; Ravetch JV
Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
[TBL] [Abstract][Full Text] [Related]
5. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
6. Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb.
Cemerski S; Chu SY; Moore GL; Muchhal US; Desjarlais JR; Szymkowski DE
Immunol Lett; 2012 Mar; 143(1):34-43. PubMed ID: 22305932
[TBL] [Abstract][Full Text] [Related]
7. Anti-FcγRIIB mAb suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of FcγRIII.
Clay CD; Strait RT; Mahler A; Khodoun MV; Finkelman FD
J Allergy Clin Immunol; 2018 Apr; 141(4):1373-1381.e5. PubMed ID: 28624610
[TBL] [Abstract][Full Text] [Related]
8. Galactosylation of IgG1 modulates FcγRIIB-mediated inhibition of murine autoimmune hemolytic anemia.
Yamada K; Ito K; Furukawa J; Nakata J; Alvarez M; Verbeek JS; Shinohara Y; Izui S
J Autoimmun; 2013 Dec; 47():104-10. PubMed ID: 24055197
[TBL] [Abstract][Full Text] [Related]
9. Anti-FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII-Specific Recall Response in vitro.
Vollack N; Friese J; Bergmann S; Cragg MS; Tiede A; Werwitzke S
Scand J Immunol; 2017 Aug; 86(2):91-99. PubMed ID: 28561280
[TBL] [Abstract][Full Text] [Related]
10. Porcine Fc gamma RIIb sub-isoforms are generated by alternative splicing.
Xia P; Liu X; Zhang Y; Duan E; Zhang Z; Chen J; Mu C; Cui B
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):386-94. PubMed ID: 22226426
[TBL] [Abstract][Full Text] [Related]
11. Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.
Stopforth RJ; Cleary KL; Cragg MS
J Clin Immunol; 2016 May; 36 Suppl 1():88-94. PubMed ID: 26922075
[TBL] [Abstract][Full Text] [Related]
12. FcγRIIB as a key determinant of agonistic antibody efficacy.
White AL; Beers SA; Cragg MS
Curr Top Microbiol Immunol; 2014; 382():355-72. PubMed ID: 25116108
[TBL] [Abstract][Full Text] [Related]
13. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.
Setiady YY; Coccia JA; Park PU
Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297
[TBL] [Abstract][Full Text] [Related]
14. Non-classical binding of a polyreactive α-type anti-idiotypic antibody to B cells.
Hernández T; de Acosta CM; López-Requena A; Moreno E; Alonso R; Fernández-Marrero Y; Pérez R
Mol Immunol; 2010; 48(1-3):98-108. PubMed ID: 20952071
[TBL] [Abstract][Full Text] [Related]
15. CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption.
Crow AR; Amash A; Lazarus AH
Transfusion; 2015 Jun; 55(6 Pt 2):1492-500. PubMed ID: 25496771
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold.
Veri MC; Burke S; Huang L; Li H; Gorlatov S; Tuaillon N; Rainey GJ; Ciccarone V; Zhang T; Shah K; Jin L; Ning L; Minor T; Moore PA; Koenig S; Johnson S; Bonvini E
Arthritis Rheum; 2010 Jul; 62(7):1933-43. PubMed ID: 20506263
[TBL] [Abstract][Full Text] [Related]
17. A role of FcgammaRIIB in the development of collagen-induced arthritis.
Nakamura A; Takai T
Biomed Pharmacother; 2004 Jun; 58(5):292-8. PubMed ID: 15194165
[TBL] [Abstract][Full Text] [Related]
18. Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors.
Ierino FL; Hulett MD; McKenzie IF; Hogarth PM
J Immunol; 1993 Mar; 150(5):1794-803. PubMed ID: 7679695
[TBL] [Abstract][Full Text] [Related]
19. FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Zhao M; Wigren M; Dunér P; Kolbus D; Olofsson KE; Björkbacka H; Nilsson J; Fredrikson GN
J Immunol; 2010 Mar; 184(5):2253-60. PubMed ID: 20097865
[TBL] [Abstract][Full Text] [Related]
20. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
